Eledon Pharmaceuticals Inc (ELDN) — Cash Flow-to-Debt Ratio
Eledon Pharmaceuticals Inc (ELDN) has a Cash Flow-to-Debt Ratio of -0.14x as of December 2025, meaning its operating cash flow of $-14.09 Million could theoretically repay 0% of its total liabilities ($100.82 Million) in one year. See Eledon Pharmaceuticals Inc (ELDN) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Eledon Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Eledon Pharmaceuticals Inc across 14 annual periods. For the full cash flow conversion analysis, see Eledon Pharmaceuticals Inc cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Eledon Pharmaceuticals Inc (2012–2025)
Year-by-year debt coverage analysis for Eledon Pharmaceuticals Inc. Check ELDN operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.62x | $-62.34 Million | $100.82 Million | ▲ +22.5% |
| 2024 | -0.80x | $-47.27 Million | $59.27 Million | ▲ +14.3% |
| 2023 | -0.93x | $-39.53 Million | $42.48 Million | ▲ +71.8% |
| 2022 | -3.30x | $-28.42 Million | $8.61 Million | ▲ +25.2% |
| 2021 | -4.41x | $-28.91 Million | $6.55 Million | ▼ -91.1% |
| 2020 | -2.31x | $-15.21 Million | $6.59 Million | ▲ +75.6% |
| 2019 | -9.45x | $-13.86 Million | $1.47 Million | ▼ -101.4% |
| 2018 | -4.69x | $-11.89 Million | $2.53 Million | ▲ +54.8% |
| 2017 | -10.38x | $-14.94 Million | $1.44 Million | ▲ +17.5% |
| 2016 | -12.58x | $-36.52 Million | $2.90 Million | ▼ -90.7% |
| 2015 | -6.60x | $-41.24 Million | $6.25 Million | ▼ -32.5% |
| 2014 | -4.98x | $-21.12 Million | $4.24 Million | ▼ -2716.2% |
| 2013 | -0.18x | $-15.48 Million | $87.55 Million | ▲ +1.8% |
| 2012 | -0.18x | $-9.33 Million | $51.86 Million | — |